Abstract
Bcl-2 family proteins have long been implicated in the pathology of chronic lymphocytic leukaemia (CLL). Indeed, a number of these proteins have been shown to have prognostic importance in this disease. The precise ways in which these proteins impact upon CLL and the ways in which they are regulated remain incompletely resolved. However, significant advances have been recently made in our understanding of how these proteins are controlled by genetic, epigenetic and microenvironmental cues. Furthermore, major progress has been made in trying to target these proteins therapeutically. Here we review the current knowledge about this family of apoptosis-regulating proteins and how they impact upon drug resistance and disease progression. We also summarise evolution in the development of Bcl-2 family inhibitors for the treatment of CLL and other cancers. (C) 2010 Elsevier Ltd. All rights reserved.
Original language | English |
---|---|
Pages (from-to) | 837 - 842 |
Number of pages | 6 |
Journal | Leukemia Research |
Volume | 34 |
Issue number | 7 |
DOIs | |
Publication status | Published - Jul 2010 |